Beyfortus (Nirsevimab)

Beyfortus helps protect babies from RSV, a virus that can cause serious lung infections. It is a single shot given into the thigh muscle. It gives the baby ready-made antibodies that block the virus from getting into cells.

Brand names:Beyfortus
Medication

What people taking Beyfortus (Nirsevimab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Beyfortus (Nirsevimab) for Respiratory Syncytial Virus (RSV) Infection?

NameHow it went

About Beyfortus (Nirsevimab)

What It's For

Nirsevimab, sold as Beyfortus, is a single injection that helps protect babies and young children from serious illness caused by respiratory syncytial virus (RSV). RSV is a common winter virus. In older children and adults it usually causes a cold, but in young infants it can spread into the small airways and lungs, causing bronchiolitis or pneumonia. Before infant protection became routine, RSV was the leading reason babies under a year old were hospitalized in the United States. Most of those babies were born healthy and full term, which is why protection is offered to all infants rather than only those with known risk factors. Beyfortus is approved for newborns and infants born during or entering their first RSV season, and for children up to 24 months old who remain vulnerable to severe RSV in their second season. US guidance recommends one dose for infants younger than 8 months heading into their first season. A second-season dose is recommended for certain children aged 8 to 19 months at higher risk, including those with chronic lung disease from prematurity who still needed treatment such as oxygen in the previous six months, children with severely weakened immune systems, some children with cystic fibrosis, and American Indian and Alaska Native children. There are two other ways to protect a baby in their first season. One is the RSV vaccine Abrysvo, given to the mother at 32 to 36 weeks of pregnancy, which passes protective antibodies to the baby before birth. The other is Enflonsia (clesrovimab), a second infant antibody shot with a similar purpose. Most babies need only one of these. A baby born at least 14 days after the mother received the RSV vaccine usually does not need Beyfortus as well, while a baby born sooner than that, or whose mother was not vaccinated or is unsure, usually does.

How It Works

When the body fights an infection, it makes antibodies, proteins that latch on to a germ and stop it from causing harm. Young babies have had little chance to build their own defenses against RSV. Beyfortus supplies a ready-made, laboratory-produced antibody instead, which is why it is called a monoclonal antibody. This is sometimes described as passive immunity: the protection comes from the antibody given, not from the baby's immune system learning to make its own, as it would after a vaccine. The antibody attaches to a protein on the surface of RSV, known as the F (fusion) protein, that the virus needs to merge with and enter the cells lining the airways. With that protein blocked, the virus has a much harder time infecting cells and spreading down into the lungs. Beyfortus has been modified so the body clears it slowly, which lets one injection keep protecting a baby for at least five months, roughly the length of a typical RSV season. It prevents illness; it is not a treatment for an RSV infection that has already started.

Dosage & Administration

Beyfortus is given by a health care provider as one injection into a muscle, usually in the thigh. For a first RSV season the dose depends on the baby's weight at the time: 50 mg for babies under 5 kilograms (about 11 pounds) and 100 mg for those at or above that weight. Children who qualify for a second-season dose receive 200 mg, given as two 100 mg injections at the same visit in different spots. Only one dose is recommended per season. Children who have heart surgery using a heart-lung bypass machine may need an extra dose afterward, because the surgery can lower antibody levels. Timing matters more than anything else about the dose. In most of the continental United States, the shot is offered from October through the end of March. Babies born during that window should ideally get it within their first week, often before leaving the birth hospital. Babies born from April to September are usually given it in the fall, shortly before RSV starts circulating. A baby who missed the ideal time can still receive it later in the season. Areas with different RSV patterns, such as Alaska, Hawaii, southern Florida and Puerto Rico, may follow local timing.

Side Effects

Side effects are uncommon. In the main clinical trials, about 1 in 100 babies had a reaction linked to the shot, and nearly all were mild or moderate. The most common were a rash within two weeks and pain, redness, swelling or firmness where the shot was given within a week. These usually pass on their own; contact the baby's care team if a rash or injection-site reaction is spreading, worsening or worrying. Serious allergic reactions have been reported but are rare. Signs include hives, trouble breathing, bluish color of the lips or skin, or a baby who becomes unusually floppy or limp. Call 911 if a child shows any of these signs after the injection.

Interactions & Warnings

Beyfortus should not be given to a child who has had a serious allergic reaction, such as anaphylaxis, to nirsevimab or any of its ingredients. Let the provider know before the injection if the child has a bleeding or clotting disorder, a low platelet count, or takes a blood thinner, since any injection into a muscle can cause bleeding or bruising in these children and may need extra care. Beyfortus can be given at the same visit as routine childhood vaccines, using a separate injection site, and it is not expected to weaken the response to those vaccines. Palivizumab, an older RSV antibody used in some high-risk babies, should not be given in the same season after Beyfortus. A child who received palivizumab in their first season can still receive Beyfortus for their second if they qualify. The antibody does not interfere with standard RSV tests, so if the child later becomes ill, testing for RSV still works.

What to Expect

The visit itself is quick, and most babies have nothing more than brief fussiness from the injection. One dose protects for at least five months, which covers a typical RSV season. In trials, babies who received Beyfortus were about 70 to 75 percent less likely to need medical care for RSV lung infection over the following five months than babies given a placebo, and in a large real-world trial they were more than 80 percent less likely to be hospitalized for RSV. Studies of routine US use show roughly 70 to 80 percent protection against RSV hospitalization. Protection is strong but not complete. A protected baby can still catch RSV, so everyday precautions such as handwashing and keeping sick people away from a newborn still help. Breathing difficulty or poor feeding during any respiratory illness should still be checked by a clinician. Because the antibody wears off after the season, most children do not need another dose; only those still at high risk are offered one before their second season.

Questions to Ask Your Doctor

  1. 1.Did the RSV vaccine I received in pregnancy, or its timing, mean my baby does not need Beyfortus?
  2. 2.When is the best time for my baby to get the shot, given our birth date and local RSV season?
  3. 3.Does my child have a condition that makes a second-season dose worthwhile?
  4. 4.Is there any reason to prefer Beyfortus or Enflonsia for my baby?
  5. 5.Can Beyfortus be given at the same visit as my baby's other vaccines?

Last reviewed • Oct 2026

Educational content, not medical advice.